2012
GABRA2 Genotype, Impulsivity, and Body Mass
Bauer LO, Yang B, Houston RJ, Kranzler HR, Gelernter J. GABRA2 Genotype, Impulsivity, and Body Mass. American Journal On Addictions 2012, 21: 404-410. PMID: 22882390, PMCID: PMC3773931, DOI: 10.1111/j.1521-0391.2012.00252.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttention Deficit Disorder with HyperactivityBody Mass IndexCase-Control StudiesConnecticutFemaleGenotypeHumansImpulsive BehaviorMaleMiddle AgedPolymorphism, Single NucleotidePsychiatric Status Rating ScalesReceptors, GABA-ASex FactorsSubstance Abuse Treatment CentersSubstance-Related DisordersConceptsBody mass indexElevated body mass indexAssociation of BMIGABRA2 genotypeSubstance dependenceAttention-deficit/hyperactivity disorderHigh-calorie foodsPrevious pregnancyMass indexElectroencephalographic featuresRisk factorsChildhood symptomsScale scoreDrug abstinenceCalorie foodsHyperactivity disorderGenetic findingsWomenLonger durationBarratt Impulsiveness ScalePsychological indicatorsGABRA2 variantsSex differencesSecond analysisBody mass
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity